---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-098530"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:42:50.044885+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Oruka files retroactively adjusted pre-merger audited financials as of Feb 6, 2024

## Summary
- Balance sheet shows $1K subscription receivable, zero cash; total stockholders' equity $1K.
- Auditor's report includes going concern qualification due to no revenue and operating losses.
- Adjustments reflect 1-for-12 reverse stock split and 6.8569 exchange ratio from August 2024 merger.
- No new operational or financial information beyond the previously closed business combination.

## SEC filing metadata
- accession: 0001213900-24-098530
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390024098530/0001213900-24-098530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390024098530/ea0221362-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-098530
- JSON: https://secwatch.observer/filing/0001213900-24-098530.json
- Plain text: https://secwatch.observer/filing/0001213900-24-098530.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.